Literature DB >> 16545933

Sensitivity of the Enzygnost anti-EBV/IgG for the determination of the Epstein-Barr virus immune status in pediatric patients.

Michael Kleines1, Simone Scheithauer, Klaus Ritter, Martin Häusler.   

Abstract

The Enzygnost Anti-EBV/IgG shows good performance for populations not defined by age. Samples from 349 pediatric outpatients were screened with the assay and with immunofluorescence assay (IFA) as the gold standard. The Enzygnost assay showed a sensitivity of 85%. Ten and one-tenth percent of EBV seropositive samples were classified as intermediate, and 4.9% were falsely determined as seronegative when compared to the standard IgG anti-virus capsid antigen (VCA) IFA. Our data suggest a limited sensitivity of the assay with samples from pediatric patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16545933     DOI： 10.1016/j.diagmicrobio.2006.01.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  3 in total

1.  Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Authors:  J Lupo; R Germi; T Semenova; M Buisson; J M Seigneurin; P Morand
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

2.  Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity.

Authors:  M Kleines; J Schiefer; A Stienen; M Blaum; K Ritter; M Häusler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-15       Impact factor: 3.267

3.  Reliability of the Siemens Enzygnost and Novagnost Epstein-Barr virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein-Barr virus immunofluorescence assay.

Authors:  Christina Kreuzer; Klaus Udo Nabeck; H Roma Levy; Elisabeth Daghofer
Journal:  BMC Infect Dis       Date:  2013-06-03       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.